Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Diane Havlir, MD

    SchoolUCSF School of Medicine
    Address1001 Potrero Ave, SFGH 80
    San Francisco CA 94110
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoResidency School of Medicine

      Collapse Overview 
      Collapse Overview
      The goal of my research is to develop therapeutic strategies that reduce the HIV burden on an individual and population level. Antiretroviral therapy has been one of the greatest successes in medicine, yet we are unable determine how to use it to eradicate HIV or deploy it to turn the HIV epidemic around globally. Further, antiretroviral therapy can reduce the global TB and malaria burden, but the optimal strategies have not been determined. Current areas of focus of our group include translational and intervention studies targeting the gut as a major residual reservoir for HIV in antiretroviral treated patients. Internationally, through the Makerere University - UCSF (MU-UCSF) research collaboration and the ACTG we are studying 1) optimal treatment strategies for HIV and TB, including new TB agents 2) strategies to reduce HIV and malaria burden in children and pregnant women. We are also developing approaches to treat HIV earlier in the course of disease in a sustainable manner that benefits the overall health, education and economics of communities in East Africa.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse NIH Awarded Grants
      Collapse Clinical Trials
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Young S, Natamba B, Luwedde F, Nyafwono D, Okia B, Osterbauer B, Natureeba P, Johnson L, Michel C, Zheng A, Robine M, Achan J, Charlebois E, Cohan D, Havlir D. "I Have Remained Strong Because of That Food": Acceptability and Use of Lipid-Based Nutrient Supplements Among Pregnant HIV-Infected Ugandan Women Receiving Combination Antiretroviral Therapy. AIDS Behav. 2015 Aug; 19(8):1535-47.
        View in: PubMed
      2. Havlir D, Gandhi M. Implementation challenges for long-acting antivirals as treatment. Curr Opin HIV AIDS. 2015 Jul; 10(4):282-9.
        View in: PubMed
      3. Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015 Apr 24; 29(7):825-30.
        View in: PubMed
      4. Yukl SA, Shergill AK, Girling V, Li Q, Killian M, Epling L, Li P, Kaiser P, Haase A, Havlir DV, McQuaid K, Sinclair E, Wong JK. Site-Specific Differences in T Cell Frequencies and Phenotypes in the Blood and Gut of HIV-Uninfected and ART-Treated HIV+ Adults. PLoS One. 2015; 10(3):e0121290.
        View in: PubMed
      5. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, Kozak B, Bloome J, Okiring J, Kakuru A, Bigira V, Kapisi J, Legac J, Gut J, Cooper RA, Kamya MR, Havlir DV, Dorsey G, Greenhouse B, Nsobya SL, Rosenthal PJ. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob Agents Chemother. 2015 Jun; 59(6):3018-30.
        View in: PubMed
      6. Havlir DV, Currier JS. CROI 2015: Complications of HIV Infection and Antiretroviral Therapy. Top Antivir Med. 2015 Mar-Apr; 23(1):56-65.
        View in: PubMed
      7. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The Effect of Malnutrition on the Pharmacokinetics and Virologic Outcomes of Lopinavir, Efavirenz and Nevirapine in Food Insecure HIV-infected Children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70.
        View in: PubMed
      8. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3.
        View in: PubMed
      9. Chamie G, Wandera B, Marquez C, Kato-Maeda M, Kamya MR, Havlir DV, Charlebois ED. Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health. 2015 Apr; 20(4):537-45.
        View in: PubMed
      10. Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015 Jan 14; 29(2):183-91.
        View in: PubMed
      11. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28; 28(18):2701-9.
        View in: PubMed
      12. Young SL, Plenty AH, Luwedde FA, Natamba BK, Natureeba P, Achan J, Mwesigwa J, Ruel TD, Ades V, Osterbauer B, Clark TD, Dorsey G, Charlebois ED, Kamya M, Havlir DV, Cohan DL. Household food insecurity, maternal nutritional status, and infant feeding practices among HIV-infected Ugandan women receiving combination antiretroviral therapy. Matern Child Health J. 2014 Nov; 18(9):2044-53.
        View in: PubMed
      13. Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Oct 1; 67(2):128-35.
        View in: PubMed
      14. Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, Chamie G, Clark TD, Rooney JF, Charlebois ED, Kamya MR, Havlir DV. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/µl in rural Uganda. AIDS. 2014 Sep 24; 28(15):2241-9.
        View in: PubMed
      15. Marquez C, Davis JL, Katamba A, Haguma P, Ochom E, Ayakaka I, Chamie G, Dorsey G, Kamya MR, Charlebois E, Havlir DV, Cattamanchi A. Assessing the quality of tuberculosis evaluation for children with prolonged cough presenting to routine community health care settings in rural Uganda. PLoS One. 2014; 9(8):e105935.
        View in: PubMed PMC4149493
      16. Marquez C, Okiring J, Chamie G, Ruel TD, Achan J, Kakuru A, Kamya MR, Charlebois ED, Havlir DV, Dorsey G. Increased Morbidity in Early Childhood Among HIV-exposed Uninfected Children in Uganda is Associated with Breastfeeding Duration. J Trop Pediatr. 2014 Dec; 60(6):434-41.
        View in: PubMed
      17. Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, Dorsey G, Rosenthal PJ. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One. 2014; 9(8):e105690.
        View in: PubMed PMC4140830
      18. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug; 11(8):e1001689.
        View in: PubMed PMC4122345
      19. Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, Charlebois ED, Clark TD, Nzarubara B, Havlir DV, Achan J, Kamya MR, Cohan D, Dorsey G. Lopinavir/Ritonavir-Based Antiretroviral Treatment (ART) Versus Efavirenz-Based ART for the Prevention of Malaria Among HIV-Infected Pregnant Women. J Infect Dis. 2014 Dec 15; 210(12):1938-45.
        View in: PubMed
      20. Luetkemeyer AF, Havlir DV, Currier JS. CROI 2014: viral hepatitis and complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2014 May; 22(2):602-15.
        View in: PubMed
      21. Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, Ruel T, Clark TD, Charlebois E, Rosenthal PJ, Havlir D, Kamya MR, Tappero JW, Dorsey G. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis. 2014 Aug; 59(3):446-53.
        View in: PubMed PMC4155440
      22. Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Kamya M, Achan J. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):535-41.
        View in: PubMed PMC3999287
      23. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 1; 65(4):423-8.
        View in: PubMed PMC3943693
      24. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
        View in: PubMed PMC4144040
      25. Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014 Mar 1; 65(3):327-32.
        View in: PubMed PMC4172444
      26. Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health. 2014 Apr; 19(4):459-68.
        View in: PubMed PMC4118739
      27. Yukl SA, Sinclair E, Somsouk M, Hunt PW, Epling L, Killian M, Girling V, Li P, Havlir DV, Deeks SG, Wong JK, Hatano H. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. AIDS. 2014 Jan 28; 28(3):439-42.
        View in: PubMed PMC4130176
      28. Moyers BS, Secemsky EA, Vittinghoff E, Wong JK, Havlir DV, Hsue PY, Tseng ZH. Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus. Am J Cardiol. 2014 Apr 1; 113(7):1260-5.
        View in: PubMed PMC3959566
      29. Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014 Apr; 52(4):1052-9.
        View in: PubMed PMC3993501
      30. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014; 9(1):e84317.
        View in: PubMed PMC3879307
      31. Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013; 13:1151.
        View in: PubMed PMC3890617
      32. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2; 382(9903):1525-33.
        View in: PubMed PMC4058441
      33. Vijayan T, Semitala FC, Matsiko N, Elyanu P, Namusobya J, Havlir DV, Kamya M, Geng EH. Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS. Clin Infect Dis. 2013 Dec; 57(12):1766-72.
        View in: PubMed PMC3840406
      34. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32.
        View in: PubMed PMC3933454
      35. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):578-84.
        View in: PubMed PMC3800282
      36. Kim LH, Arinaitwe E, Nzarubara B, Kamya MR, Clark TD, Okong P, Charlebois ED, Havlir DV, Cohan D. Acceptability and feasibility of serial HIV antibody testing during pregnancy/postpartum and male partner testing in Tororo, Uganda. AIDS Care. 2014; 26(3):360-6.
        View in: PubMed
      37. Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/µL under routine program conditions in Uganda. Clin Infect Dis. 2013 Nov; 57(9):1343-50.
        View in: PubMed PMC3792723
      38. Christopoulos KA, Havlir DV. Overcoming the human immunodeficiency virus obstacle course. JAMA Intern Med. 2013 Jul 22; 173(14):1344-5.
        View in: PubMed
      39. Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis. 2013 Oct 15; 208(8):1212-20.
        View in: PubMed PMC3778964
      40. Ades V, Mwesigwa J, Natureeba P, Clark TD, Plenty A, Charlebois E, Achan J, Kamya MR, Havlir DV, Cohan D, Ruel TD. Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in Rural Uganda. J Trop Pediatr. 2013 Dec; 59(6):441-6.
        View in: PubMed PMC3842848
      41. Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED. Household ventilation and tuberculosis transmission in Kampala, Uganda. Int J Tuberc Lung Dis. 2013 Jun; 17(6):764-70.
        View in: PubMed
      42. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, Katabira E, Lange J, Lima VD, Patterson T, Strathdee SA, Williams B, Montaner J. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013 Apr 24; 27(7):1159-65.
        View in: PubMed
      43. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
        View in: PubMed PMC3719885
      44. Luetkemeyer AF, Havlir DV, Currier JS. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med. 2013 Apr-May; 21(2):62-74.
        View in: PubMed
      45. Cohan D, Mwesigwa J, Natureeba P, Aliba Luwedde F, Ades V, Plenty A, Kakuru A, Achan J, Clark T, Osterbauer B, Kamya M, Havlir D. WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity. J Acquir Immune Defic Syndr. 2013 Mar 1; 62(3):e101-3.
        View in: PubMed PMC3738916
      46. Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20; 27(4):627-34.
        View in: PubMed PMC3809760
      47. Ikilezi G, Achan J, Kakuru A, Ruel T, Charlebois E, Clark TD, Rosenthal PJ, Havlir D, Kamya MR, Dorsey G. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg. 2013 Apr; 88(4):744-6.
        View in: PubMed PMC3617863
      48. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb; 56(4):598-605.
        View in: PubMed PMC3552523
      49. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29; 367(22):2110-8.
        View in: PubMed PMC3664297
      50. Tseng ZH, Moyers B, Secemsky EA, Havlir DV, Hsue PY. PR Interval and sudden cardiac death in patients with HIV infection. J Infect Dis. 2013 Jan 1; 207(1):199-200.
        View in: PubMed PMC3523799
      51. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012 Nov 13; 26(17):2121-33.
        View in: PubMed PMC3819503
      52. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 1; 61(3):310-6.
        View in: PubMed PMC3511816
      53. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/µL in a public health setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7.
        View in: PubMed PMC3501330
      54. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7(8):e43400.
        View in: PubMed PMC3423366
      55. Young S, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, Arinaitwe E, Clark T, Ades V, Plenty A, Charlebois E, Ruel T, Kamya M, Havlir D, Cohan D. Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One. 2012; 7(8):e41934.
        View in: PubMed PMC3413694
      56. Havlir D, Beyrer C. The beginning of the end of AIDS? N Engl J Med. 2012 Aug 23; 367(8):685-7.
        View in: PubMed
      57. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2012 Jun-Jul; 20(2):48-60.
        View in: PubMed
      58. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, Havlir DV, Hsue PY. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012 May 22; 59(21):1891-6.
        View in: PubMed PMC3356565
      59. Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriëns J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis. 2012 May; 54 Suppl 4:S245-9.
        View in: PubMed PMC3338313
      60. Riley ED, Neilands TB, Moore K, Cohen J, Bangsberg DR, Havlir D. Social, structural and behavioral determinants of overall health status in a cohort of homeless and unstably housed HIV-infected men. PLoS One. 2012; 7(4):e35207.
        View in: PubMed PMC3338834
      61. Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, Rosenthal PJ, Dorsey G, Achan J, Akello C, Kamya MR, Wong JK. Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis. 2012 Apr; 54(7):1001-9.
        View in: PubMed PMC3297647
      62. Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc. 2012; 15(2):17396.
        View in: PubMed PMC3499795
      63. Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011 Nov 28; 25(18):2269-78.
        View in: PubMed PMC3572727
      64. Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. J Acquir Immune Defic Syndr. 2011 Nov 1; 58(3):e96-9.
        View in: PubMed PMC4120944
      65. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
        View in: PubMed PMC3327101
      66. Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M. The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clin Infect Dis. 2011 Nov; 53(10):1008-14.
        View in: PubMed PMC3193829
      67. Kay J, Wanzira H, Sandison T, Kakuru A, Bigira V, Kamya M, Homsy J, Tappero JW, Havlir D, Dorsey G, Ruel T. Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda. J Trop Pediatr. 2012 Jun; 58(3):194-9.
        View in: PubMed PMC3530275
      68. Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, Mupere E, Mugyenyi P, Boom WH, Mugerwa RD, Havlir DV, Whalen CC. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4? T-cell counts of = 350 cells/µL. J Infect Dis. 2011 Sep 15; 204(6):884-92.
        View in: PubMed PMC3156928
      69. Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med. 2011 Nov 15; 184(10):1107-13.
        View in: PubMed PMC3361323
      70. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois ED, Feeney ME. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis. 2011 Sep; 53(6):592-9.
        View in: PubMed PMC3160805
      71. Dowdy DW, Geng EH, Christopoulos KA, Kahn JS, Hare CB, Wlodarczyk D, Havlir DV. Mortality among antiretroviral-eligible patients in an urban public clinic. J Acquir Immune Defic Syndr. 2011 Aug 1; 57(4):297-300.
        View in: PubMed PMC3159809
      72. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11; 365(6):493-505.
        View in: PubMed PMC3200068
      73. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2011 May-Jun; 19(2):58-68.
        View in: PubMed
      74. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods. 2011 Aug; 175(2):261-5.
        View in: PubMed PMC3827908
      75. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011 Apr 15; 52(8):1046-9.
        View in: PubMed PMC3070031
      76. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, Nalukwago S, Charlebois E, Havlir D, Mayanja-Kizza H, Whalen CC, Boom WH. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. J Infect Dis. 2011 Apr 1; 203(7):992-1001.
        View in: PubMed PMC3068037
      77. Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK, Achan J. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011 Jan 1; 56(1):44-50.
        View in: PubMed PMC3078046
      78. Charlebois ED, Ruel TD, Gasasira AF, Achan J, Kateera F, Akello C, Cao H, Dorsey G, Rosenthal PJ, Ssewanyana I, Kamya MR, Havlir DV. Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):330-5.
        View in: PubMed PMC3025136
      79. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010 Oct 23; 24(16):2451-60.
        View in: PubMed PMC2997807
      80. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010 Nov 15; 202(10):1553-61.
        View in: PubMed PMC2997806
      81. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010 Oct; 14(10):1295-302.
        View in: PubMed PMC3033769
      82. Li P, Ruel T, Fujimoto K, Hatano H, Yukl S, Eller LA, Liegler T, Kamya M, Gassasira A, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK. Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes. J Virol Methods. 2010 Dec; 170(1-2):115-20.
        View in: PubMed PMC3280821
      83. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010 Sep 1; 202(5):705-16.
        View in: PubMed PMC2916952
      84. Charlebois ED, Havlir DV. "A bird in the hand...": a commentary on the test and treat approach for HIV. Arch Intern Med. 2010 Aug 9; 170(15):1354-6.
        View in: PubMed
      85. Chamie G, Charlebois ED, Srikantiah P, Walusimbi-Nanteza M, Mugerwa RD, Mayanja H, Okwera A, Whalen CC, Havlir DV. Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis. 2010 Aug 1; 51(3):359-62.
        View in: PubMed PMC2919368
      86. Bebell LM, Pilcher CD, Dorsey G, Havlir D, Kamya MR, Busch MP, Dunn Williams J, Nugent CT, Bentsen C, Rosenthal PJ, Charlebois ED. Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS. 2010 Jul 31; 24(12):1945-52.
        View in: PubMed PMC2909782
      87. Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, Ruel T, Kateera F, Meya DN, Havlir D, Rosenthal PJ, Dorsey G. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010; 9:177.
        View in: PubMed PMC2903607
      88. Boivin MJ, Ruel TD, Boal HE, Bangirana P, Cao H, Eller LA, Charlebois E, Havlir DV, Kamya MR, Achan J, Akello C, Wong JK. HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS. 2010 May 15; 24(8):1163-70.
        View in: PubMed PMC2880483
      89. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S245-54.
        View in: PubMed PMC3032796
      90. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral treatment. Top HIV Med. 2010 Apr-May; 18(2):57-65.
        View in: PubMed PMC3032798
      91. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010 Apr 20; 74(16):1260-6.
        View in: PubMed PMC2860482
      92. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS One. 2010; 5(2):e9138.
        View in: PubMed PMC2825253
      93. Newman PM, Wanzira H, Tumwine G, Arinaitwe E, Waldman S, Achan J, Havlir D, Rosenthal PJ, Dorsey G, Clark TD, Cohan D. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J. 2009; 8:254.
        View in: PubMed PMC2781026
      94. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 1; 51(4):424-9.
        View in: PubMed
      95. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009 Jun 1; 23(9):1109-18.
        View in: PubMed PMC2739977
      96. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2009 Apr-May; 17(2):57-67.
        View in: PubMed
      97. Getahun H, Havlir D, Granich R, Reid A, Jaramillo E, Nunn P. Paradigm shift to address drug resistant tuberculosis in people living with HIV needed, and needed now. Trop Med Int Health. 2009 Apr; 14(4):376-8.
        View in: PubMed
      98. Ruel T, Ssewanyana I, Achan J, Gasasira A, Kamya MR, Kekitiinwa A, Wong JK, Cao H, Havlir D, Charlebois ED. Dynamics of T cell activation accompanying CD4 recovery in antiretroviral treated HIV-infected Ugandan children. Clin Immunol. 2009 Jun; 131(3):410-4.
        View in: PubMed PMC3032795
      99. Davis JL, Huang L, Kovacs JA, Masur H, Murray P, Havlir DV, Worodria WO, Charlebois ED, Srikantiah P, Cattamanchi A, Huber C, Shea YR, Chow Y, Fischer SH. Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis. Clin Infect Dis. 2009 Mar 15; 48(6):725-32.
        View in: PubMed PMC2657807
      100. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Günthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology. 2009 Apr 25; 387(1):98-108.
        View in: PubMed
      101. Ssewanyana I, Baker CA, Ruel T, Bousheri S, Kamya M, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Cao H. The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from Uganda. AIDS Res Hum Retroviruses. 2009 Jan; 25(1):65-71.
        View in: PubMed PMC2858297
      102. Srikantiah P, Wong JK, Liegler T, Walusimbi M, Mayanja-Kizza H, Kayanja HK, Mugerwa RD, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis. J Acquir Immune Defic Syndr. 2008 Dec 1; 49(4):458-60.
        View in: PubMed
      103. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis. 2008 Dec; 12(12):1370-5.
        View in: PubMed
      104. Chakaya J, Getahun H, Granich R, Havlir D. Confronting TB/HIV in the era of increasing anti-TB drug resistance. J Int AIDS Soc. 2008; 11:6.
        View in: PubMed PMC2588552
      105. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008 Aug 1; 47(3):421-4.
        View in: PubMed PMC2586907
      106. Havlir DV. HIV integrase inhibitors--out of the pipeline and into the clinic. N Engl J Med. 2008 Jul 24; 359(4):416-8.
        View in: PubMed
      107. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23; 300(4):423-30.
        View in: PubMed
      108. Ruel TD, Achan J, Gasasira AF, Charlebois ED, Mehbratu T, Rosenthal PJ, Dorsey G, Kamya MR, Kekitiinwa A, Wong J, Havlir DV. HIV RNA suppression among HIV-infected Ugandan children with measles. J Acquir Immune Defic Syndr. 2008 Jun 1; 48(2):225-7.
        View in: PubMed PMC3040680
      109. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 May 15; 358(20):2095-106.
        View in: PubMed PMC3885902
      110. Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T, Charlebois E, Staedke SG, Kekitiinwa A, Rosenthal PJ, Havlir D, Dorsey G. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis. 2008 Apr 1; 46(7):985-91.
        View in: PubMed
      111. Currier JS, Havlir DV. Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Complications of HIV disease and therapy. Top HIV Med. 2008 Apr-May; 16(1):23-30.
        View in: PubMed
      112. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008 Feb 1; 197(3):411-9.
        View in: PubMed
      113. Bebell LM, Gasasira A, Kiggundu M, Dokomajilar C, Kamya MR, Charlebois ED, Havlir D, Rosenthal PJ, Dorsey G. HIV-1 infection in patients referred for malaria blood smears at government health clinics in Uganda. J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):624-30.
        View in: PubMed
      114. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007 Dec 15; 45(12):1633-9.
        View in: PubMed
      115. Ssewanyana I, Elrefaei M, Dorsey G, Ruel T, Jones NG, Gasasira A, Kamya M, Nakiwala J, Achan J, Charlebois E, Havlir D, Cao H. Profile of T cell immune responses in HIV-infected children from Uganda. J Infect Dis. 2007 Dec 1; 196(11):1667-70.
        View in: PubMed
      116. Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, Charlebois ED, Rosenthal PJ, Havlir D, Dorsey G. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007 Oct 1; 21(15):2059-66.
        View in: PubMed
      117. Srikantiah P, Walusimbi MN, Kayanja HK, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS. 2007 Sep 12; 21(14):1972-4.
        View in: PubMed
      118. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis. 2007 Aug 15; 196 Suppl 1:S46-51.
        View in: PubMed
      119. Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials. 2007 Jul-Aug; 8(4):193-204.
        View in: PubMed
      120. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007 May 15; 195(10):1426-36.
        View in: PubMed
      121. Currier JS, Havlir DV. Complications of HIV disease and therapy. Top HIV Med. 2007 Apr-May; 15(2):40-7.
        View in: PubMed
      122. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15; 44(6):889-91.
        View in: PubMed
      123. Srikantiah P, Lin R, Walusimbi M, Okwera A, Luzze H, Whalen CC, Boom WH, Havlir DV, Charlebois ED. Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention. Int J Tuberc Lung Dis. 2007 Feb; 11(2):168-74.
        View in: PubMed PMC2846511
      124. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007 Apr 1; 175(7):737-42.
        View in: PubMed PMC1899289
      125. Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006 Nov 1; 194(9):1309-18.
        View in: PubMed
      126. Gasasira AF, Dorsey G, Kamya MR, Havlir D, Kiggundu M, Rosenthal PJ, Charlebois ED. False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. J Clin Microbiol. 2006 Aug; 44(8):3021-4.
        View in: PubMed PMC1594619
      127. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med. 2006 Jul 13; 355(2):173-81.
        View in: PubMed
      128. Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Charlebois E, Havlir DV. Antiretroviral therapy and TB. Trop Doct. 2006 Apr; 36(2):73-9.
        View in: PubMed
      129. Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2006 Mar-Apr; 14(1):27-35.
        View in: PubMed
      130. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Jan 1; 41(1):31-6.
        View in: PubMed PMC4050666
      131. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis. 2006 Jan 1; 193(1):9-15.
        View in: PubMed
      132. Havlir DV, Hammer SM. Patents versus patients? Antiretroviral therapy in India. N Engl J Med. 2005 Aug 25; 353(8):749-51.
        View in: PubMed
      133. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 2005 Jul; 49(7):2983-5.
        View in: PubMed PMC1168637
      134. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005 May 1; 191(9):1410-8.
        View in: PubMed
      135. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2005 Mar-Apr; 13(1):16-23.
        View in: PubMed
      136. Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, Miller MD, Wong JK. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis. 2005 Apr 1; 191(7):1164-8.
        View in: PubMed
      137. Srikantiah P, Charlebois E, Havlir DV. Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics. J Infect Dis. 2005 Jan 15; 191(2):147-9.
        View in: PubMed
      138. Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis. 2004 Dec 1; 39(11):1699-704.
        View in: PubMed
      139. Havlir DV, O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1; 38(11):1599-604.
        View in: PubMed
      140. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. Top HIV Med. 2004 Mar-Apr; 12(1):31-45.
        View in: PubMed
      141. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 2003 Nov 7; 17(16):2345-9.
        View in: PubMed
      142. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, Wong JK. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003 Oct; 77(20):11212-9.
        View in: PubMed PMC224988
      143. Havlir DV. Strategic approaches to antiretroviral treatment. Top HIV Med. 2003 Jul-Aug; 11(4):145-9.
        View in: PubMed
      144. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med. 2003 Jun 5; 348(23):2279-81.
        View in: PubMed
      145. Havlir DV, Currier JS. Complications of HIV infection and antiretroviral therapy. Top HIV Med. 2003 May-Jun; 11(3):86-91.
        View in: PubMed
      146. Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4819-24.
        View in: PubMed PMC153639
      147. Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrob Agents Chemother. 2002 Dec; 46(12):3877-82.
        View in: PubMed PMC132738
      148. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 2002 Dec; 46(12):3907-16.
        View in: PubMed PMC132776
      149. Jones D, Havlir DV. Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med. 2002 Sep; 23(3):665-74.
        View in: PubMed
      150. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Sep 1; 31(1):20-6.
        View in: PubMed
      151. Havlir D, Vella S, Hammer S. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. AIDS. 2002 Jul 5; 16(10):7-9.
        View in: PubMed
      152. Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retroviruses. 2002 Jul 1; 18(10):699-704.
        View in: PubMed
      153. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002 Apr; 8(4):379-85.
        View in: PubMed
      154. Hogg RS, Havlir D, Miller V, Montaner JS. To stop or not to stop: that is the question, but what is the answer? AIDS. 2002 Mar 29; 16(5):787-9.
        View in: PubMed
      155. Appay V, Hansasuta P, Sutton J, Schrier RD, Wong JK, Furtado M, Havlir DV, Wolinsky SM, McMichael AJ, Richman DD, Rowland-Jones SL, Spina CA. Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS. 2002 Jan 25; 16(2):161-70.
        View in: PubMed
      156. Havlir DV. Structured intermittent treatment for HIV disease: Necessary concession or premature compromise? Proc Natl Acad Sci U S A. 2002 Jan 8; 99(1):4-6.
        View in: PubMed PMC117502
      157. Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu TM, Emini EA, Shiver JW. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol. 2002 Jan; 76(1):185-94.
        View in: PubMed PMC135696
      158. Havlir D. Adding two new drug classes improves outcome in salvage therapy. AIDS Clin Care. 2001 Oct; 13(10):99.
        View in: PubMed
      159. Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK, Richman DD. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS. 2001 Jul 27; 15(11):1379-88.
        View in: PubMed
      160. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001 Jul 11; 286(2):171-9.
        View in: PubMed
      161. Frost SD, Günthard HF, Wong JK, Havlir D, Richman DD, Leigh Brown AJ. Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology. 2001 Jun 5; 284(2):250-8.
        View in: PubMed
      162. Huang W, De Gruttola V, Fischl M, Hammer S, Richman D, Havlir D, Gulick R, Squires K, Mellors J. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis. 2001 May 15; 183(10):1455-65.
        View in: PubMed
      163. Günthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, Gamagami R, Emini E, Haase A, Richman DD, Wong JK. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis. 2001 May 1; 183(9):1318-27.
        View in: PubMed
      164. Schacker T, Little S, Connick E, Gebhard K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong JK, Schooley RT, Richman D, Corey L, Haase AT. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis. 2001 Feb 15; 183(4):555-62.
        View in: PubMed
      165. Havlir DV, Torriani FJ, Schrier RD, Huang JY, Lederman MM, Chervenak KA, Boom WH. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol. 2001 Jan; 39(1):298-303.
        View in: PubMed PMC87718
      166. Zhou XJ, Havlir DV, Richman DD, Acosta EP, Hirsch M, Collier AC, Tebas P, Sommadossi JP. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS. 2000 Dec 22; 14(18):2869-76.
        View in: PubMed
      167. Havlir DV, Schrier RD, Torriani FJ, Chervenak K, Hwang JY, Boom WH. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis. 2000 Dec; 182(6):1658-63.
        View in: PubMed
      168. Ioannidis JP, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. AIDS. 2000 Jul 28; 14(11):1481-8.
        View in: PubMed
      169. Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, Fox L, Kessler H, Fife KH, Richman DD. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis. 2000 Jul; 182(1):321-5.
        View in: PubMed
      170. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000 Jul 4; 133(1):35-9.
        View in: PubMed
      171. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000 Jul 3; 192(1):63-75.
        View in: PubMed PMC1887711
      172. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, Richman DD. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS. 2000 May 5; 14(7):821-6.
        View in: PubMed
      173. Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000 Feb; 181(2):522-31.
        View in: PubMed
      174. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000 Jan 12; 283(2):229-34.
        View in: PubMed
      175. Schacker T, Little S, Connick E, Gebhard-Mitchell K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong JK, Richman D, Corey L, Haase AT. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis. 2000 Jan; 181(1):354-7.
        View in: PubMed
      176. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, Veazey RS, Notermans D, Little S, Danner SA, Richman DD, Havlir D, Wong J, Jordan HL, Schacker TW, Racz P, Tenner-Racz K, Letvin NL, Wolinsky S, Haase AT. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999 Nov 12; 286(5443):1353-7.
        View in: PubMed
      177. Günthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, Spina CA, Havlir DV, Hezareh M, Looney DJ, Richman DD, Wong JK. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999 Nov; 73(11):9404-12.
        View in: PubMed PMC112975
      178. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med. 1999 Sep 20; 190(6):841-50.
        View in: PubMed PMC2195636
      179. Dunne MW, Bozzette S, McCutchan JA, Dubé MP, Sattler FR, Forthal D, Kemper CA, Havlir D. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet. 1999 Sep 11; 354(9182):891-5.
        View in: PubMed
      180. Vázquez-Rosales G, García Lerma JG, Yamamoto S, Switzer WM, Havlir D, Folks TM, Richman DD, Heneine W. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. AIDS Res Hum Retroviruses. 1999 Sep 1; 15(13):1191-200.
        View in: PubMed
      181. Zhang ZQ, Schuler T, Cavert W, Notermans DW, Gebhard K, Henry K, Havlir DV, Günthard HF, Wong JK, Little S, Feinberg MB, Polis MA, Schrager LK, Schacker TW, Richman DD, Corey L, Danner SA, Haase AT. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1999 Apr 27; 96(9):5169-72.
        View in: PubMed PMC21835
      182. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999 Feb 4; 340(5):367-73.
        View in: PubMed
      183. Dubé MP, Torriani FJ, See D, Havlir DV, Kemper CA, Leedom JM, Tilles JG, McCutchan JA, Sattler FR. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. Clin Infect Dis. 1999 Jan; 28(1):136-8.
        View in: PubMed
      184. Havlir DV, Dubé MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998 Dec; 27(6):1369-75.
        View in: PubMed
      185. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Boone G, Richman DD. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998 Oct 29; 339(18):1261-8.
        View in: PubMed
      186. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood. 1998 Aug 15; 92(4):1317-23.
        View in: PubMed
      187. Günthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998 Jul 1; 14(10):869-76.
        View in: PubMed
      188. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998 Jul 1; 280(1):35-41.
        View in: PubMed
      189. Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998 Mar; 72(3):2422-8.
        View in: PubMed PMC109542
      190. Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. J Infect Dis. 1998 Mar; 177(3):595-9.
        View in: PubMed
      191. Havlir DV, Lange JM. New antiretrovirals and new combinations. AIDS. 1998; 12 Suppl A:S165-74.
        View in: PubMed
      192. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997 Nov 14; 278(5341):1291-5.
        View in: PubMed
      193. Wong JK, Günthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A. 1997 Nov 11; 94(23):12574-9.
        View in: PubMed PMC25043
      194. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, Dezfuli MG, Bozzette SA, Bartok AE, Leedom JM, Tilles JG, McCutchan JA. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis. 1997 Nov; 176(5):1225-32.
        View in: PubMed
      195. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997 Sep 11; 337(11):734-9.
        View in: PubMed
      196. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol. 1997 Mar; 71(3):2059-71.
        View in: PubMed PMC191294
      197. Havlir DV, Richman DD. The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy. Springer Semin Immunopathol. 1997; 18(3):267-83.
        View in: PubMed
      198. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996 Nov; 70(11):7894-9.
        View in: PubMed PMC190861
      199. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, Bozzette SA, McCutchan JA. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996 Aug 8; 335(6):392-8.
        View in: PubMed
      200. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien M. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996 Jun 6; 334(23):1491-7.
        View in: PubMed
      201. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med. 1996 Jun 1; 124(11):984-94.
        View in: PubMed
      202. Torriani FJ, Behling CA, McCutchan JA, Haubrich RH, Havlir DV. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis. 1996 Apr; 173(4):942-9.
        View in: PubMed
      203. Katlama C, Havlir DV. Newer nucleosides: lamivudine and stavudine. AIDS. 1996; 10 Suppl A:S135-43.
        View in: PubMed
      204. Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virol. 1996 Jan; 70(1):628-34.
        View in: PubMed PMC189857
      205. Havlir D, McLaughlin MM, Richman DD. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208. J Infect Dis. 1995 Nov; 172(5):1379-83.
        View in: PubMed
      206. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995 Mar; 171(3):537-45.
        View in: PubMed
      207. Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1; 8(2):141-51.
        View in: PubMed
      208. Richman DD, Havlir D. Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. Drugs. 1995; 49 Suppl 1:9-16; discussion 38-40.
        View in: PubMed
      209. Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis. 1994 Dec; 170(6):1601-5.
        View in: PubMed
      210. Havlir DV. Mycobacterium avium complex: advances in therapy. Eur J Clin Microbiol Infect Dis. 1994 Nov; 13(11):915-24.
        View in: PubMed
      211. Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med. 1994 Oct 1; 121(7):510-2.
        View in: PubMed
      212. Kemper CA, Havlir D, Bartok AE, Kane C, Camp B, Lane N, Deresinski SC. Transient bacteremia due to Mycobacterium avium complex in patients with AIDS. J Infect Dis. 1994 Aug; 170(2):488-93.
        View in: PubMed
      213. Kemper CA, Havlir D, Haghighat D, Dubé M, Bartok AE, Sison JP, Yao Y, Yangco B, Leedom JM, Tilles JG, et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis. 1994 Jul; 170(1):157-64.
        View in: PubMed
      214. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar; 68(3):1660-6.
        View in: PubMed PMC236624
      215. Havlir D, Kemper CA, Deresinski SC. Reproducibility of lysis-centrifugation cultures for quantification of Mycobacterium avium complex bacteremia. J Clin Microbiol. 1993 Jul; 31(7):1794-8.
        View in: PubMed PMC265634
      216. Flanigan T, Whalen C, Turner J, Soave R, Toerner J, Havlir D, Kotler D. Cryptosporidium infection and CD4 counts. Ann Intern Med. 1992 May 15; 116(10):840-2.
        View in: PubMed
      217. Havlir DV, van der Kuyp F, Duffy E, Marshall R, Hom D, Ellner JJ. A 19-year follow-up of tuberculin reactors. Assessment of skin test reactivity and in vitro lymphocyte responses. Chest. 1991 May; 99(5):1172-6.
        View in: PubMed
      218. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens. Infect Immun. 1991 Feb; 59(2):665-70.
        View in: PubMed PMC257808
      219. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest. 1991 Feb; 87(2):729-33.
        View in: PubMed PMC296366
      220. Wallis RS, Alde SL, Havlir DV, Amir-Tahmasseb MH, Daniel TM, Ellner JJ. Identification of antigens of Mycobacterium tuberculosis using human monoclonal antibodies. J Clin Invest. 1989 Jul; 84(1):214-9.
        View in: PubMed PMC303972
      221. Havlir D, Brown L, Rousseau GK. Do not resuscitate discussions in a hospital-based home care program. J Am Geriatr Soc. 1989 Jan; 37(1):52-4.
        View in: PubMed
      222. Havlir D, Tierney LM. Biochemical and clinical aspects of amyloidosis. West J Med. 1987 Jul; 147(1):65-70.
        View in: PubMed PMC1025816
      223. Havlir DV, Witt MD, Sande M. A 32-year-old man with the acquired immunodeficiency syndrome and pneumococcal meningitis. West J Med. 1987 May; 146(5):618-9.
        View in: PubMed PMC1307427
      224. Havlir DV, Murillo S, Robles E, Trejos A, Mata L. Nutritional status of the elderly in Palmares, Costa Rica. Arch Latinoam Nutr. 1983 Jun; 33(2):409-22.
        View in: PubMed
      225. Brown T, Havlir D. Typhoid fever. N Y State J Med. 1982 Dec; 82(13):1792, 1875.
        View in: PubMed
      Diane's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP